Sir, a couple of questions from my side. First one on the margins , which have been very strong this quarter again at about 28 odd percent and that's despite ~ Rs. 70 crore PBT loss in the pharma segment. So, given this, and the fact that we have been maintaining an EBITDA margin guidance of 26% for this year, should we expect that this current quarter's margin sustains for the rest of the year ? And would you like to upgrade your guidance for the full year?
The second one was just with regard to the pharma segment. I understand there is some deferment of revenues there, but if you could please help us understand whether this is coming primarily from the Archimica business in Italy, the API business or is it the CDMO shipments from Therachem in India? And given this kind of start to the year, a week start, what kind of revenue number could we work with for the full year for pharma?